Sarepta Shares Drop Following Report of Patient Death in Early-Stage Trial

In a blow that sent shockwaves through the biotech world, Sarepta shares tumbled following a report of a patient’s death during an early-stage clinical trial. The news not only rocked investors but also reignited the conversation around the risks tied to cutting-edge genetic treatments. The fallout? Billions in market value were wiped out, and growing unease in the entire stock market, especially among biotech and AI stocks.